Pacira BioSciences Investors Encouraged to Join Class Action for Securities Fraud Claims

Investors Affected by Pacira BioSciences' Stock Decline encouraged to Take Action

In February 2025, Levi & Korsinsky, LLP announced their notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX) regarding a potential class action lawsuit targeting alleged securities fraud. The firm invites affected investors to join the legal proceedings in an effort to recover losses incurred between August 2, 2023, and August 8, 2024.

Background of the Case

On August 9, 2024, Pacira released a significant press statement concerning a lawsuit related to patent infringement against eVenus. In this statement, the company reported that the court ruled that Pacira's U.S. Patent No. 11,033,495, which is crucial for their primary product Exparel, was deemed invalid. This patent is vital for Pacira as it generates around 80% of the company's revenue. The invalidation raised skepticism over the status of other patents held by Pacira, which could lead to increased competition from generic formulations entering the market, further straining the financial standing of the company.

Following this release, Pacira's stock plummeted over 47% from a closing price of $22.36 on August 8 to just $11.70 the next day. This drastic decline has left many investors searching for avenues to reclaim their losses.

Call to Action for Investors

Any shareholders who experienced financial loss during the designated period are encouraged to act swiftly. Levi & Korsinsky invites these investors to express their interest in being appointed as a lead plaintiff by March 14, 2025. However, it is crucial to communicate that not serving as a lead plaintiff does not impact the potential for recovery from any settlements or damages awarded. Potential plaintiffs can initiate contact through various channels provided by the law firm, including an informative link for additional details and direct engagement with the legal team.

No Financial Risk Involved

Investors should note that participating in this class action involves no risk or costs upfront. Levi & Korsinsky operates under a contingency structure, which means that members of the class action may potentially receive compensation without any out-of-pocket expenses or obligations.

Levi & Korsinsky's Credentials

Levi & Korsinsky has a substantial history in handling complex securities litigation, having secured hundreds of millions of dollars for investors over the past two decades. The firm is recognized as one of the top securities litigation firms in the United States by ISS Securities Class Action Services, which ranks Levi & Korsinsky in their Top 50 Report consistently over several years. This extensive experience is essential for investors looking to navigate the intricacies of securities law effectively.

How to Contact

Investors interested in participating or seeking further information can reach out directly to Joseph E. Levi, Esq. via email or phone. The firm emphasizes its commitment to support clients through this challenging experience and ensure they receive due diligence in addressing their grievances.

Investors affected by the stock decline of Pacira BioSciences should not delay in seeking justice and can capitalize on the legal support provided by Levi & Korsinsky to potentially recover their losses through this class action lawsuit.